Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
98 hedge funds and large institutions have $85.5M invested in Endocyte, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 9 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 25
0% more funds holding
Funds holding: 98 → 98 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
22% less capital invested
Capital invested by funds: $109M → $85.5M (-$23.5M)
27% less call options, than puts
Call options by funds: $936K | Put options by funds: $1.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$670K |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$602K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$472K |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$324K |
| 5 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.61M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$976K |
| 3 |
QI
QS Investors
New York
|
-$540K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$523K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$376K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
B
101
Bailard
Foster City,
California
| – | -$351K | -56,000 | Closed |
|
|
MLICM
102
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$210K | -33,505 | Closed |
|
|
CMBA
103
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$139K | -22,250 | Closed |
|
|
TI
104
Trexquant Investment
Stamford,
Connecticut
| – | -$98K | -15,800 | Closed |
|
|
HH
105
Hilltop Holdings
Dallas,
Texas
| – | -$67K | -10,720 | Closed |
|
106
Principal Financial Group
Des Moines,
Iowa
| – | -$67K | -10,600 | Closed |
|
|
PCM
107
Prelude Capital Management
New York
| – | -$49K | -7,900 | Closed |
|
ECYT Hedge Fund Activity: Q2 2015 in Review
98 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2015, worth a combined $85.5M — down 22% from $109M a quarter earlier.
Fund positioning in ECYT was balanced in Q2 2015: 9 funds opened new positions, 9 closed out, 38 added to existing stakes and 25 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $670K. The largest seller was Fidelity Investments, cutting an estimated $6.61M.
- 98 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $85.5M of Endocyte, Inc. Common Stock stock for Q2 2015, down 22% quarter-over-quarter.
- 9 funds opened new Endocyte, Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of 0 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q2 2015 was Royal Bank of Canada, an estimated $670K added.
- The largest Endocyte, Inc. Common Stock seller in Q2 2015 was Fidelity Investments, an estimated $6.61M sold.
Based on aggregated 13F filings for Q2 2015.